Last reviewed · How we verify
non-pegylated interferon
non-pegylated interferon is a Small molecule drug developed by Biogen. It is currently in Phase 2 development. Also known as: IFN.
Non-pegylated interferon is a protein-based treatment used to study various conditions, including Acute Hepatitis C, Hepatitis C, and Chronic Hepatitis C, as well as Insulin Resistance. It is a natural protein with synonyms such as INTERFERON ALFA, and its exact formulation and combination with other treatments, like Ribavirin and Telaprevir, may vary depending on the specific clinical trial.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Biogen is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | non-pegylated interferon |
|---|---|
| Also known as | IFN |
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma (PHASE2)
- Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B (PHASE4)
- Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study
- Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy (PHASE3)
- The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV (PHASE2)
- Impact of Fatty Liver on Hepatitis B Therapy
- Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia (PHASE2)
- Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- non-pegylated interferon CI brief — competitive landscape report
- non-pegylated interferon updates RSS · CI watch RSS
- Biogen portfolio CI
Frequently asked questions about non-pegylated interferon
What is non-pegylated interferon?
Who makes non-pegylated interferon?
Is non-pegylated interferon also known as anything else?
What development phase is non-pegylated interferon in?
Related
- Manufacturer: Biogen — full pipeline
- Also known as: IFN
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing